Lisa Lewis, NP
Primary Care · Danville, VANPI 1255982906
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 266 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 39.5% of the total. Among primary care clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 266 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$499
- Novo Nordisk$464
- AstraZeneca$286
- Lilly USA, LLC$196
- Otsuka America Pharmaceutical, Inc.$161
- plus $809 from 19 others
What the payments were for
- Food & beverage$3,989100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 137 | $1,575 |
| Pfizer | 33 | $499 |
| Novo Nordisk | 21 | $464 |
| AstraZeneca | 9 | $286 |
| Lilly USA, LLC | 11 | $196 |
| Otsuka America Pharmaceutical, Inc. | 4 | $161 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $134 |
| Amgen(2 entities) | 4 | $75 |
| Bayer | 4 | $72 |
| Corcept Therapeutics | 3 | $65 |
| Ironshore Pharmaceuticals Inc. | 3 | $58 |
| Exact Sciences | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 3 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Astellas Pharma US Inc | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Dynavax Technologies Corporation | 2 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| GSK | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,989 in reported general payments places this provider in the 90th percentile of 142 primary care providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $22,180 |
| JanuviaSitagliptin Phosphate | 21 | $18,683 |
| OzempicSemaglutide | 14 | $15,967 |
| MounjaroTirzepatide | 12 | $12,164 |
| LinzessLinaclotide | 14 | $10,709 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $1,609 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $1,562 |
| Atorvastatin Calcium | 129 | $989 |
| Omeprazole | 90 | $830 |
| Amiodarone Hcl | 13 | $529 |
| Losartan Potassium | 90 | $523 |
| Fluticasone Propionate | 65 | $510 |
| Levothyroxine Sodium | 89 | $509 |
| Azithromycin | 85 | $425 |
| Mupirocin | 56 | $407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $499 | $22,18027 claims |
| Novo NordiskOzempic | $464 | $15,96714 claims |
| Lilly USA, LLCMounjaro | $196 | $12,16412 claims |
| AbbVieLinzess | $1,575 | $10,70914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 142 primary care providers in Virginia.
Other primary care in Danville
- Sara WeaverDanville$5K
- Ann Marie KnightDanville$1K
- Rebecca GrinsellRichmond$12K
- Jennifer CampbellNewport News$8K
- Tien MaAnnandale$7K
- Michael CogginAshland$7K
- Erin StewartFredericksburg$6K
- Lawanda WoodNorfolk$6K
- Luis Rivera PenaFalls Church$4K
- Erika RobinsonFredericksburg$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.